SCHEMBL111436

SCHEMBL111436

COC(=O)c1cccnc1Br

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.55
MAP2K1 Q02750 1/20 0.53
KDM4E B2RXH2 5/20 0.51
POLB P06746 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
PKM P14618 1/20 0.50
ATM Q13315 1/20 0.50
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.48
ALDH1A1 P00352 5/20 0.47
CFTR P13569 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CNR2 P34972 1/20 0.47
SLC6A3 Q01959 1/20 0.46
ALOX15 P16050 1/20 0.45
HTT P42858 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29574644 1.00 TDP1 (0.55) TDP1MAP2K1KDM4EPOLBL3MBTL1
SCHEMBL1427354 0.81 LMNA (0.43) TDP1KDM4EPOLBL3MBTL1LMNA
SCHEMBL812065 0.81 KDM4E (0.59) TDP1MAP2K1KDM4EPOLBL3MBTL1
SCHEMBL8422472 0.81 POLB (0.44) TDP1KDM4EPOLBL3MBTL1LMNA
SCHEMBL5401801 0.81 TSHR (0.59) TDP1L3MBTL1TSHRALDH1A1HSD17B10
SCHEMBL28120694 0.80 TDP1 (0.50) TDP1MAP2K1KDM4EPOLBL3MBTL1
SCHEMBL69990 0.79 L3MBTL1 (0.62) TDP1MAP2K1KDM4EPOLBL3MBTL1
SCHEMBL31185958 0.79 KDM4E (0.57) TDP1MAP2K1KDM4EPOLBL3MBTL1
SCHEMBL107721 0.79 KDM4E (0.57) TDP1MAP2K1KDM4EPOLBL3MBTL1
SCHEMBL162558 0.79 TDP1 (0.57) TDP1MAP2K1KDM4EPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743457-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE 4M THERAPEUTICS INC. (US) 2026-05-20 EP disclosed
US-12628548-B2 Organometallic compound and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2026-05-12 US disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-20260035398-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES UNIV ARIZONA STATE (US) 2026-02-05 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
US-12459899-B2 Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient DIGMBIO, Inc. (KR) 2025-11-04 US disclosed
US-12312366-B2 Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2025-05-27 US disclosed
WO-2025101780-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT, INC. (US) 2025-05-15 WO disclosed
EP-4547246-A2 COMPOUNDS AS INHIBITORS OF AXL Arcus Biosciences, Inc. (US) 2025-05-07 EP disclosed
CN-119528915-A Compounds for inhibiting apoptosis and methods of making the same 中国科学院上海有机化学研究所 2025-02-28 CN disclosed
US-5283242-A Hypotensive agents, cardiotonic agents AMERICAN HOME PRODUCTS CORPORATION (US) 1994-02-01 US disclosed
EP-0548291-A1 PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1993-06-30 EP disclosed
EP-0244728-B1 USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION BAYER AG (DE) 1992-11-11 EP disclosed
WO-1992005156-A1 PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1992-04-02 WO disclosed
EP-0244728-A2 Use of heteroarylethyl amines to stimulate animal growth, heteroarylethyl amines and process for their preparation BAYER AG (DE) 1987-11-11 EP disclosed
EP-0053011-B1 NEW HERBICIDAL NICOTINAMIDE DERIVATIVES MAY & BAKER LIMITED (GB) 1985-04-03 EP disclosed
EP-0053011-A1 New herbicidal nicotinamide derivatives MAY & BAKER LIMITED (GB) 1982-06-02 EP disclosed
US-4321387-A Process for the preparation of optically active nicotine analogs PHILIP MORRIS, INCORPORATED (US) 1982-03-23 US disclosed
US-3992536-A SEDATIVES AND MUSCLE RELAXANTS BOEHRINGER INGELHEIM GMBH (DT) 1976-11-16 US disclosed
US-3931185-A SEDATIVES, MUSCLE RELAXANT BOEHRINGER INGELHEIM GMBH (DT) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 TDP1 125/4885MAP2K1 2246/4885KDM4E 3719/4885
US-20260035398-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES LBR, SCO2, RAD54L TDP1 4113/4885MAP2K1 2106/4885KDM4E 3523/4885
US-12628548-B2 Organometallic compound and organic light-emitting device including the same TBL2, TBL3, CD274 TDP1 3823/4885MAP2K1 1623/4885KDM4E 3027/4885
US-12459899-B2 Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient PARP1, PARP2, PARP11 TDP1 52/4885MAP2K1 2701/4885KDM4E 3425/4885
US-12312366-B2 Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues PAICS, DNTT, PNPO TDP1 1929/4885MAP2K1 4430/4885KDM4E 2613/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 TDP1 30/4885MAP2K1 1183/4885KDM4E 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.